153 related articles for article (PubMed ID: 2023111)
1. An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis.
White DB; Walawander CA; Tung Y; Grasela TH
J Pharmacokinet Biopharm; 1991 Feb; 19(1):87-112. PubMed ID: 2023111
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of hypothesis testing for comparing two populations using NONMEM analysis.
White DB; Walawander CA; Liu DY; Grasela TH
J Pharmacokinet Biopharm; 1992 Jun; 20(3):295-313. PubMed ID: 1522482
[TBL] [Abstract][Full Text] [Related]
3. Estimating inestimable standard errors in population pharmacokinetic studies: the bootstrap with Winsorization.
Ette EI; Onyiah LC
Eur J Drug Metab Pharmacokinet; 2002; 27(3):213-24. PubMed ID: 12365204
[TBL] [Abstract][Full Text] [Related]
4. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the standard approach and the NONMEM approach in the estimation of bioavailability in man.
Combrink M; McFadyen ML; Miller R
J Pharm Pharmacol; 1997 Jul; 49(7):731-3. PubMed ID: 9255720
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of population (NONMEM) pharmacokinetic parameter estimates.
Vozeh S; Maitre PO; Stanski DR
J Pharmacokinet Biopharm; 1990 Apr; 18(2):161-73. PubMed ID: 2348382
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus.
Staatz CE; Tett SE
Eur J Clin Pharmacol; 2002 Dec; 58(9):597-605. PubMed ID: 12483452
[TBL] [Abstract][Full Text] [Related]
8. On the recording of sample times and parameter estimation from repeated measures pharmacokinetic data.
Sun H; Ette EI; Ludden TM
J Pharmacokinet Biopharm; 1996 Dec; 24(6):637-50. PubMed ID: 9300354
[TBL] [Abstract][Full Text] [Related]
9. Interpretation of simulation studies for efficient estimation of population pharmacokinetic parameters.
Ette EI; Kelman AW; Howie CA; Whiting B
Ann Pharmacother; 1993 Sep; 27(9):1034-9. PubMed ID: 8117353
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients.
Bruno R; Iliadis MC; Lacarelle B; Cosson V; Mandema JW; Le Roux Y; Montay G; Durand A; Ballereau M; Alasia M
J Pharmacokinet Biopharm; 1992 Dec; 20(6):653-69. PubMed ID: 1302767
[TBL] [Abstract][Full Text] [Related]
11. The importance of modeling interoccasion variability in population pharmacokinetic analyses.
Karlsson MO; Sheiner LB
J Pharmacokinet Biopharm; 1993 Dec; 21(6):735-50. PubMed ID: 8138894
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data.
Sheiner LB; Beal SL
J Pharmacokinet Biopharm; 1983 Jun; 11(3):303-19. PubMed ID: 6644555
[TBL] [Abstract][Full Text] [Related]
13. NONMEM and NPEM2 population modeling: a comparison using tobramycin data in neonates.
de Hoog M; Schoemaker RC; van den Anker JN; Vinks AA
Ther Drug Monit; 2002 Jun; 24(3):359-65. PubMed ID: 12021626
[TBL] [Abstract][Full Text] [Related]
14. Balanced designs in longitudinal population pharmacokinetic studies.
Ette EI; Sun H; Ludden TM
J Clin Pharmacol; 1998 May; 38(5):417-23. PubMed ID: 9602953
[TBL] [Abstract][Full Text] [Related]
15. The back-step method--method for obtaining unbiased population parameter estimates for ordered categorical data.
Kjellsson MC; Jönsson S; Karlsson MO
AAPS J; 2004 Aug; 6(3):e19. PubMed ID: 15760104
[TBL] [Abstract][Full Text] [Related]
16. Hyperparameter estimation using stochastic approximation with application to population pharmacokinetics.
Mentré F; Mallet A; Steimer JL
Biometrics; 1988 Sep; 44(3):673-83. PubMed ID: 3203126
[TBL] [Abstract][Full Text] [Related]
17. Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition.
Marathe A; Van Wart S; Mager DE
J Pharmacokinet Pharmacodyn; 2011 Apr; 38(2):223-35. PubMed ID: 21165681
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of flucytosine: comparison and validation of three models using STS, NPEM, and NONMEM.
Vermes A; Math t RA; van der Sijs IH; Dankert J; Guchelaar HJ
Ther Drug Monit; 2000 Dec; 22(6):676-87. PubMed ID: 11128235
[TBL] [Abstract][Full Text] [Related]
19. Covariate detection in population pharmacokinetics using partially linear mixed effects models.
Bonate PL
Pharm Res; 2005 Apr; 22(4):541-9. PubMed ID: 15846461
[TBL] [Abstract][Full Text] [Related]
20. Inter-study variability in population pharmacokinetic meta-analysis: when and how to estimate it?
Laporte-Simitsidis S; Girard P; Mismetti P; Chabaud S; Decousus H; Boissel JP
J Pharm Sci; 2000 Feb; 89(2):155-67. PubMed ID: 10688745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
